KRAS and lung carcinoma: In summary, we demonstrate that it is highly feasible to utilise frozen EBUS-TBNA in patients with advanced lung cancer to quantify TMB and other putative immunotherapy biomarkers including PD-L1 copy number and KRAS mutation status.